About Allarity Therapeutics, Inc. - Common stock (ALLR)
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that target specific molecular drivers of tumors. The company utilizes its proprietary drug development platform to identify and enhance the effectiveness of treatments tailored for individual patient profiles, particularly in cases of advanced or difficult-to-treat cancers. By leveraging advanced technologies, Allarity aims to improve patient outcomes through personalized medicine approaches that align therapies with the unique characteristics of a patient's tumor, ultimately striving to bring more effective options to the oncology landscape. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Power Metallic Mines Inc. (TSX-V: PNPN; OTCQB: PNPNF; Frankfurt: IVV) today announced the appointment of Seamus O’Regan Jr., Canada’s former Minister of Energy & Natural Resources, to its Board of Directors.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company’s Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity’s development over the past two years.
